Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer
Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer
Sentinel Node Disection No Worse Than Axillary
Triple-Negative Breast Cancer Equally Aggressive in Whites
RG7204 Meets Endpoints Of Extending Survival, PFS
INSPIRE Enrollment Stopped; Thromboembolism Risk Cited
Tarceva Reaches Endpoint Early: Longer PFS Than Chemo Alone
mTOR Inhibitor Improves PFS In Metastatic Sarcoma Patients
Afinitor Tablet Doubles PFS; Lowers Progression Risk 65%
Study Links Native American Ancestry to Leukemia Relapse
Study Explores Reasons Women Avoid Mammograms
Hormone Therapy At Menopause Linked to More Breast Cancer Risk
Children of Male Cancer Survivors Have Highrt Risk of Birth Defects
Study Finds No Link Between Tumor Grade and Relapse Risk
Clinical Trials Approved By NCI CTEP Last Month
Rituxan Approved as Maintenance For Advanced Follicular Lymphoma
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Brown University reaches agreement with Trump administration to restore funding
- Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Harvey Risch, critic of COVID-19 response, tapped by White House to serve as chair of the President’s Cancer Panel
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- John Byrd brings blood cancer expertise to solid tumor, immunology powerhouse at UPMC
